# Evaluation of the Pharmacokinetics, Safety, and Tolerability of IM Letrozole LEBE in Healthy Post-menopausal Women

> **NCT06315205** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Rovi Pharmaceuticals Laboratories** · enrollment: 90 (estimated)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Letrozole LEBE 75 mg
- **DRUG:** Letrozole LEBE 150 mg
- **DRUG:** Letrozole LEBE 225 mg

## Key facts

- **NCT ID:** NCT06315205
- **Lead sponsor:** Rovi Pharmaceuticals Laboratories
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-07-26
- **Primary completion:** 2026-03
- **Final completion:** 2026-03
- **Target enrollment:** 90 (ESTIMATED)
- **Last updated:** 2026-03-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06315205

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06315205, "Evaluation of the Pharmacokinetics, Safety, and Tolerability of IM Letrozole LEBE in Healthy Post-menopausal Women". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT06315205. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*